Welcome to Circassia
Circassia is a specialty biopharmaceutical company focused on developing world-class immunotherapies. These include a new class of T-cell vaccines designed to treat a broad range of allergies, and therapies to combat autoimmune conditions such as rheumatoid arthritis and psoriasis. The Company has made rapid progress since its establishment in 2006, and several of its products are currently in mid- to late-stage development, having successfully completed a number of phase II clinical studies.
Circassia’s history
Circassia was originally founded to develop and commercialise a range of allergy T-cell vaccines based on the Company’s proprietary ToleroMune® technology, which has the potential to transform current treatment. With its portfolio of allergy T-cell vaccines progressing rapidly through clinical development, Circassia has broadened its pipeline into other areas of immunotherapy. These include treatments for autoimmune diseases, with the Company initially focusing on rheumatoid arthritis and psoriasis.
Circassia’s team
Circassia is managed by a strong team of life science entrepreneurs and scientists, and is chaired by Sir Richard Sykes, the former Chairman of GlaxoSmithKline. The management team brings a wealth of experience from major pharmaceutical and biotechnology companies as well as the specialty pharmaceutical sector. Circassia is well funded having raised £60m in April 2011 and is supported by a syndicate of leading institutional and venture capital investors.
Did you know?
Over 20% of the population are allergic to grass pollen